The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Tue, 17th Dec 2019 16:39

(Alliance News) - Midatech Pharma PLC on Monday said it has secured a notification from NASDAQ Stock Market LLC stating that Midatech share price is not in compliance with the minimum bid requirement for continued listing on NASDAQ Capital Market in New York.

Midatech explained that one of the NASDAQ listing rules requires the company's shares to maintain a minimum bid price of USD1.00 per share. A failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Based on the Midatech's American depositary share price of USD0.58 as of Tuesday, it no longer meets the minimum bid price requirement. Each ADS represents 20 Midatech shares. In London, Midatech shares closed up 4.4% at 2.40 pence each on Tuesday.

Looking ahead, the AIM-listed biotechnology firm said it has a grace period of 180 days, or until June 8 next year, to regain compliance with the minimum bid price requirement, meaning that Midatech shares should meet or exceed USD1.00 per share for at least ten consecutive business days during the compliance period.

If the shares do not regain compliance with the minimum bid price requirement during the compliance period, Midatech said it may be eligible for an additional grace period of 180 calendar day.

If it does not regain compliance during the initial grace period and is not eligible for an additional grace period, its shares will be delisted from NASDAQ Capital Market.

In that event, Midatech said it may appeal such determination to a hearing panel.

"The company intends to monitor the bid price of its depositary shares during the compliance period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods," Midatech said in its statement Tuesday.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2018 11:02

Midatech Pharma 2017 Loss Narrows On Costs And Impairments Fall

LONDON (Alliance News) - Midatech Pharma PLC said Monday its 2017 loss narrowed on lower costs and reduced impairments as its approaches 2018 with a number of key "inflection" points for

Read more
15 Mar 2018 12:36

Midatech Pharma CEO Phillips To Step Down, COO Cook Steps Up

LONDON (Alliance News) - Pharmaceutical firm Midatech Pharma PLC said Thursday its Chief Executive Jim Phillips will leave the company after five years at the who is departing

Read more
22 Nov 2016 13:29

Midatech Pharma receives upfront access fee

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop

Read more
15 Nov 2016 12:04

Midatech Pharma chooses MTR104 for liver cancer treatment

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l

Read more
31 Oct 2016 09:39

BROKER RATINGS SUMMARY: HSBC Raises IAG To Hold From Reduce

Read more
11 Oct 2016 10:30

Midatech To Raise GBP14 Million Via Placing And Open Offer (ALLISS)

Read more
30 Sep 2016 08:41

Midatech Says Trials Of Drug Using Its Gold Nanoparticles Commence

Read more
2 Sep 2016 12:07

Midatech Pharma's revenues increases due to US sales

(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s

Read more
7 Jul 2016 09:05

Midatech-Cardiff University Collaboration Gets Diabetes Grant

Read more
27 Jun 2016 11:29

Midatech Pharma Issues Final Shares To Settle Q Chip Acquisition (ALLISS)

Read more
18 May 2016 09:39

Midatech Signals Further Focus On "Better Suited" Oncology Treatments

Read more
11 May 2016 08:49

Midatech Pharma Trading Ahead Of Expectations On Strong Revenue Growth

Read more
26 Apr 2016 09:27

Midatech Pharma Gets Positive Data From Q-Octreotide Trial

Read more
21 Apr 2016 07:55

Midatech Pharma Sees Positive Dosing Data In Uveitis Programme

Read more
13 Apr 2016 08:24

Midatech Loss Widens On Acquisition Costs, But Revenue Surges

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.